Your browser doesn't support javascript.
loading
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto, Paolo A; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance, Ana M; Dalle, Stephane; Cowey, C Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Márquez-Rodas, Iván; Butler, Marcus O; Maio, Michele; Middleton, Mark R; de la Cruz-Merino, Luis; Arenberger, Petr; Atkinson, Victoria; Hill, Andrew; Fecher, Leslie A; Millward, Michael; Khushalani, Nikhil I; Queirolo, Paola; Lobo, Maurice; de Pril, Veerle; Loffredo, John; Larkin, James; Weber, Jeffrey.
Afiliação
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: paolo.ascierto@gmail.com.
  • Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Mandalá M; Papa Giovanni XIII Hospital, Bergamo, Italy.
  • Gogas H; National and Kapodistrian University of Athens, Athens, Greece.
  • Arance AM; Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain.
  • Dalle S; Hospices Civils de Lyon, Pierre Bénite, France.
  • Cowey CL; Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.
  • Schenker M; Oncology Center Sf Nectarie, Craiova, Romania.
  • Grob JJ; Department of Dermatology, Aix-Marseille University, Hôpital de la Timone, Marseille, France.
  • Chiarion-Sileni V; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Márquez-Rodas I; Department of Medical Oncology, General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain.
  • Butler MO; Department of Immuno-oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Maio M; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Middleton MR; Department of Oncology, Churchill Hospital, Oxford, UK.
  • de la Cruz-Merino L; Department of Clinical Oncology, Hospital University Virgen Macarena, Seville, Spain.
  • Arenberger P; Department of Dermatology, Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Atkinson V; Division of Cancer Services, Gallipoli Medical Research Foundation, University of Queensland, Brisbane, QLD, Australia.
  • Hill A; Department of Medical Oncology, Tasman Health Care, Southport, QLD, Australia.
  • Fecher LA; Department of Medical Oncology, Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
  • Millward M; Department of Internal Medicine, University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Khushalani NI; Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Queirolo P; IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Lobo M; Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • de Pril V; Department of Global Regulatory and Safety Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
  • Loffredo J; Clinical Biomarkers, Bristol Myers Squibb, Princeton, NJ, USA.
  • Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
  • Weber J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Lancet Oncol ; 21(11): 1465-1477, 2020 11.
Article em En | MEDLINE | ID: mdl-32961119
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article